Astria Therapeutics (NASDAQ:ATXS) Upgraded at Citizens Jmp

Citizens Jmp upgraded shares of Astria Therapeutics (NASDAQ:ATXS) to a strong-buy rating in a research report sent to investors on Friday morning,Zacks.com reports.

ATXS has been the subject of several other reports. JMP Securities began coverage on shares of Astria Therapeutics in a report on Friday. They issued an “outperform” rating and a $26.00 price objective for the company. Oppenheimer increased their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Thursday, January 23rd. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $25.67.

Astria Therapeutics Stock Performance

Astria Therapeutics stock opened at $7.86 on Friday. Astria Therapeutics has a one year low of $7.16 and a one year high of $16.90. The firm has a market capitalization of $443.57 million, a P/E ratio of -3.76 and a beta of 0.70. The company has a 50-day simple moving average of $8.93 and a 200-day simple moving average of $10.43.

Institutional Investors Weigh In On Astria Therapeutics

Large investors have recently modified their holdings of the stock. New York State Common Retirement Fund increased its position in Astria Therapeutics by 67.0% in the fourth quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 4,300 shares during the period. Quest Partners LLC boosted its position in Astria Therapeutics by 180.8% during the third quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 5,798 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Astria Therapeutics in the fourth quarter valued at $107,000. PDT Partners LLC acquired a new stake in Astria Therapeutics during the 3rd quarter valued at $140,000. Finally, SG Americas Securities LLC acquired a new stake in Astria Therapeutics during the third quarter worth approximately $155,000. 98.98% of the stock is currently owned by institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.